Yank are you saying that our results bettered Humira's results even though MESO trial tested patients that failed 1,2 or more than 3 drug treatments?
Are you saying our trial results (although small in number) were comparable or better than Abbvies results.... while showing far less side effects?
Obviously this is ground breaking on so many levels.
Silvu did not want to rock the boat and go for first line approval. Smart
This trial will allow the drug to be used after standard of care.... for now. He is playing nice for a deal/partnership
Fantastic results that have shown the longevity of these cells.
Imagine if they could give 2 or 3 doses when it is warranted
Two GREAT takeaways, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.196B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.636M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 95109 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 376066 | 28 |
View Market Depth
| Last trade - 15.57pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |